MeiraGTx Holdings (MeiraGTx Holdings) GF Value : $12.25 (As of Apr. 30, 2024)

View and export this data going back to 2018. Start your Free Trial

What is MeiraGTx Holdings GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-30), MeiraGTx Holdings's share price is $4.91. MeiraGTx Holdings's GF Value is $12.25. Therefore, MeiraGTx Holdings's Price-to-GF-Value for today is 0.40.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes MeiraGTx Holdings is Possible Value Trap, Think Twice.

MeiraGTx Holdings (NAS:MGTX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

MeiraGTx Holdings's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	4.91	/	12.25
	=	0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings GF Value Related Terms

Thank you for viewing the detailed overview of MeiraGTx Holdings's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MeiraGTx Holdings (MeiraGTx Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MeiraGTx Holdings PLC (NAS:MGTX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

328:Germany

Address

450 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.meiragtx.com

MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.

Executives

Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Robert K Zeldin	officer: Chief Medical Officer	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Robert J Wollin	officer: General Counsel and Secretary	450 EAST 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Debra Yu	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Alexandria Forbes	director, officer: President & CEO	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Richard Giroux	officer: Chief Operating Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Stuart Naylor	director, officer: Chief Dev. Officer	C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Thomas E Shenk	director	C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016
Nicole Seligman	director	C/O VIACOM INC., 1515 BROADWAY, NEW YORK NY 10036
Perceptive Advisors Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Ellen Hukkelhoven	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003